[HTML][HTML] Amiodarone in ventricular arrhythmias: still a valuable resource?

L Pannone, G D'Angelo, S Gulletta… - Reviews in …, 2021 - imrpress.com
Ventricular arrhythmias still represent an important cause of morbidity and mortality,
especially in patients with heart failure and reduced left ventricular ejection fraction …

[HTML][HTML] Antiarrhythmic drug therapy to avoid implantable cardioverter defibrillator shocks

J Abboud, JR Ehrlich - Arrhythmia & electrophysiology review, 2016 - ncbi.nlm.nih.gov
Implantable cardioverter defibrillators (ICDs) are effective in the prevention of arrhythmic
sudden cardiac death. Many patients receiving an ICD are affected by heart failure and are …

Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators

J Vijgen, G Botto, J Camm, CJ Hoijer, W Jung… - Europace, 2009 - academic.oup.com
Patients with an implantable cardioverter defibrillator (ICD) have an ongoing risk of sudden
incapacitation that might cause harm to others while driving a car. Driving restrictions vary …

Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease

A Miyazaki, H Ohuchi, K Kurosaki, S Kamakura… - Circulation …, 2008 - jstage.jst.go.jp
Background Sotalol is a class III antiarrhythmic agent that is highly effective for
tachyarrhythmias in adults, but its efficacy in patients with congenital heart disease (CHD) …

European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart …

B Gorenek, G Boriani, GA Dan, L Fauchier… - EP …, 2018 - academic.oup.com
Endocrine disorders are associated with various tachyarrhythmias, including atrial fibrillation
(AF), ventricular tachycardia (VT), ventricular fibrillation (VF), and bradyarrhythmias. Along …

Developing a safe intravenous sotalol dosing regimen

JC Somberg, RA Preston, V Ranade… - American journal of …, 2010 - journals.lww.com
Recently, an intravenous formulation of sotalol has been approved by the food and drug
administration for substitution for oral therapy in patients who are unable to take oral sotalol …

QRS prolongation is associated with high defibrillation thresholds during cardioverter-defibrillator implantations in patients with hypertrophic cardiomyopathy

T Nagai, T Kurita, K Satomi, T Noda, H Okamura… - Circulation …, 2009 - jstage.jst.go.jp
Background: Although high defibrillation threshold (DFT) is a major and unavoidable clinical
problem after implantation of an implantable cardioverter defibrillator (ICD), little is known …

Consensus Statement: Consensus Statement of the European Heart Rhythm Association: Updated Recommendations for Driving by Patients with Implantable …

J Vijgen, G Botto, J Camm, CJ Hoijer… - European journal of …, 2010 - academic.oup.com
Patients with an implantable cardioverter defibrillator (ICD) have an ongoing risk of sudden
incapacitation that might cause harm to others while driving a car. Driving restrictions vary …

Defibillator electrogram T wave alternans as a predictor of spontaneous ventricular tachyarrhythmias in defibrillator recipients

JW Kim, HN Pak, JH Park, GB Nam, SK Kim… - Circulation …, 2009 - jstage.jst.go.jp
Background Although T wave alternans (TWA) and the T wave peak-to-end (Tpte) interval
are associated with vulnerability to ventricular tachyarrhythmia (VT), no previous reports …

Hypertrophic cardiomyopathy and implantable defibrillators in Sweden: inappropriate shocks and complications requiring surgery

P Magnusson, F Gadler, P Liv… - Journal of Cardiovascular …, 2015 - Wiley Online Library
Inappropriate ICD Shocks and Complications in HCM Introduction The expanded use of
implantable cardioverter‐defibrillators (ICDs) to prevent sudden cardiac death (SCD) in …